Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response

International Journal of Cancer

Volumn 109, Issue 6, 2004, Pages 909-918

  Di Modugno, Francesca ^a   Bronzi, Giovanna ^a   Scanlan, Matthew J ^b   Del Bello, Duilia ^a   Cascioli, Simona ^a   Venturo, Irene ^a   Botti, Claudio ^a   Nicotra, Maria Rita ^c   Mottolese, Marcella ^a   Natali, Pier Giorgio ^a   Santoni, Angela ^d   Jager, Elke ^e   Nisticò, Paola ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c CNR   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e KRANKENHAUS NORDWEST   (Germany)

Author keywords

Cytotoxic T lymphocyte; Major histocompatibility complex; Tumor immunity

Indexed keywords

CANCER ANTIBODY; COMPLEMENTARY DNA; HLA A2 ANTIGEN; HUMAN MENA PROTEIN; IMMUNOGLOBULIN G ANTIBODY; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANALYTIC METHOD; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL ADHESION; CELL MOTILITY; CELLULAR IMMUNITY; CHROMOSOME 1; CONTROLLED STUDY; CYTOSKELETON; CYTOTOXIC T LYMPHOCYTE; DNA ISOLATION; DNA LIBRARY; DNA SCREENING; HLA SYSTEM; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SEROLOGIC ANALYSIS OF COMPLEMENTARY DNA EXPRESSION LIBRARY; SEROLOGY; SERUM; TUMOR IMMUNITY; WESTERN BLOTTING;

ANTIBODIES, NEOPLASM; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CARCINOMA, LOBULAR; CARRIER PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; CYTOSKELETAL PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HLA-A2 ANTIGEN; HUMANS; IMMUNITY, CELLULAR; IMMUNOHISTOCHEMISTRY; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 9244236729     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20094     Document Type: Article

References (42)

1. Chen YT, Scanlan MJ, Obata Y, Old LJ. Identification of human tumor antigens by serological expression cloning. In: Rosenberg SA, ed. Principles and practice of biologic therapy of cancer. Philadelphia: Lippincott Williams and Wilkins, 2000. 557-70.
2. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
3. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
4. Spiotto MT, Reth MA, Schreiber H. Genetic changes occurring in established tumors rapidly stimulate new antibody responses. Proc Natl Acad Sci USA 2003;100:5425-30.
5. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995;92:11810-3.
6. Nishikawa H, Tanida K, Ikeda H, Sakakura M, Miyahara Y, Aota T, Mukai K, Watanabe M, Kuribayashi K, Old LJ, Shiku H. Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proc Natl Acad Sci USA 2001;98:14571-6.
7. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach Y, Arand M, Knuth A, Old LJ. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-54.
8. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998;187:265-70.
9. Jager E, Jager D, Karbach J, Chen YT, Ritter G, Nagata Y, Gnjatic S, Stockert E, Arand M, Old LJ, Knuth A. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med 2000;191:625-30.
10. + cancers. Proc Natl Acad Sci USA 2000;97:12198-203.
11. Bear JE, Svitkina TM, Krause M, Schafer DA, Loureiro JJ, Strasser GA, Maly IV, Chaga OY, Cooper JA, Borisy GG, Gertler FB. Antagonism between Ena/ VASP proteins and actin filament capping regulates fibroblast motility. Cell 2002;109:509-21.
12. Vasioukhin V, Bauer C, Yin M, Fuchs E. Directed actin polymerization is the driving force for epithelial cell-cell adhesion. Cell 2000;100:209-19.
13. Wulfkuhle JD, Sgroi DC, Krutzsch H, McLean K, McGarvey K, Knowlton M, Chen S, Shu H, Sahin A, Kurek R, Wallwiener D, Merino MJ, et al. Proteomics of human breast ductal carcinoma in situ. Cancer Res 2002;62:6740-9.
14. Kellner R, Lichtenfels R, Atkins D, Bukur J, Ackermann A, Beck J, Brenner W, Melchior S, Seliger B. Targeting of tumor associated antigens in renal cell carcinoma using proteome-based analysis and their clinical significance. Proteomics 2002;2:1743-51.
15. Anichini A, Mortarini R, Fossati G, Parmiani G. Phenotypic profile of clones from early cultures of human metastatic melanomas and its modulation by recombinant interferon gamma. Int J Cancer 1986;38:505-11.
16. Nistico P, De Berardinis P, Morrone S, Alonzi T, Buono C, Venturo I, Natali PG. Generation and characterization of two human alpha/beta T cell clones: recognizing autologous breast tumor cells through an HLA- and TCR/CD3-independent pathway. J Clin Invest 1994;94:1426-31.
17. Brodsky FM, Parham P, Barnstable CJ, Crumpton MJ, Bodmer WF. Monoclonal antibodies for analysis of the HLA system. Immunol Rev 1979;47:3-61.
18. Jager E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee SY, Jungbluth A, Jager D, Arand M, Ritter G, et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 2000;97:4760-5.
19. Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, Ziegler A. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell 1978;14:9-20.
20. Digiesi G, Giacomini P, Fraioli R, Mariani M, Nicotra MR, Segatto O, Natali PG. Production and characterization of murine mAbs to the extracellular domain of human neu oncogene product GP185HER2. Hybridoma 1992;11:519-27.
21. Nistico P, Mottolese M, Cascioli S, Benevolo M, Del Bello D, Di Modugno F, Rubiu O, Gentile FP, Botti C, Venturo I, Natali PG. Host immunosurveillance contributes to the control of erbB-2 overexpression in HLA-A2-breast-cancer patients. Int J Cancer 1999;84:598-603.
22. Zheng L, Li S, Boyer TG, Lee WH. Lessons learned from BRCA1 and BRCA2. Oncogene 2000;19:6159-75.
23. Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, Ishov AM, Tommerup N, Vissing H, Sekido Y, Minna J, Borodovsky A, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998;16:1097-112.
24. Li S, Ku CY, Farmer AA, Cong YS, Chen CF, Lee WH. Identification of a novel cytoplasmic protein that specifically binds to nuclear localization signal motifs. J Biol Chem 1998;273:6183-9.
25. Gertler FB, Niebuhr K, Reinhard M, Wehland J, Soriano P. Mena, a relative of VASP and Drosophila Enabled, is implicated in the control of microfilament dynamics. Cell 1996;87:227-39.
26. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999;50:213-9.
27. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-75.
28. Di Modugno F, Mammi C, Rosano L, Rubiu O, Nistico P, Chersi A. MHC-peptide binding: dimers of cysteine-containing nonapeptides bind with high affinity to HLA-A2.1 class I molecules. J Immunother 1997;20:431-6.
29. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995;181:2109-17.
30. Walker BD, Flexner C, Birch-Limberger K, Fisher L, Paradis TJ, Aldovini A, Young R, Moss B, Schooley RT. Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1989;86:9514-8.
31. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA. Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
32. Jager E, Stockert E, Zidianakis Z, Chen YT, Karbach J, Jager D, Arand M, Ritter G, Old LJ, Knuth A. Humoral immune responses of cancer patients against "cancer-testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer 1999;84:506-10.
33. Lollini PL, Forni G. Cancer immunoprevention: tracking down persistent tumor antigens. Trends Immunol 2003;24:62-6.
34. Rubio-Godoy V, Dutoit V, Rimoldi D, Lienard D, Lejeune F, Speiser D, Guillaume P, Cerottini JC, Romero P, Valmori D. Discrepancy between ELISPOT IFN-γ secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life. Proc Natl Acad Sci USA 2001;98:10302-7.
35. Yu Z, Restifo NP. Cancer vaccines: progress reveals new complexities. J Clin Invest 2002;110:289-94.
36. Gambaryan S, Hauser W, Kobsar A, Glazova M, Walter U. Distribution, cellular localization, and postnatal development of VASP and Mena expression in mouse tissues. Histochem Cell Biol 2001;116:535-43.
37. Hansen MH, Nielsen H, Ditzel HJ. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci USA 2001;98:12659-64.
38. Bear JE, Loureiro JJ, Libova I, Fassler R, Wehland J, Gertler FB. Negative regulation of fibroblast motility by Ena/VASP proteins. Cell 2000;101:717-28.
39. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
40. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002;2:91-100.
41. Gordon LA, Mulligan KT, Maxwell-Jones H, Adams M, Walker RA, Jones JL. Breast cell invasive potential relates to the myoepithelial phenotype. Int J Cancer. 2003;106:8-16.
42. Scanlan MJ, Welt S, Gordon CM, Chen YT, Gure AO, Stockert E, Jungbluth AA, Ritter G, Jager D, Jager E, Knuth A, Old LJ. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res 2002;62:4041-7.